ResearcherChina Pharmaceutical UniversityNo recent work listed

Luyong Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1164-7371; OpenAlex author ID A5003128598. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2012: 2 papers

Papers 2

Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells. Last author DOI 10.1016/j.gene.2012.04.088 ↗
Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. Last author DOI 10.1111/j.1742-4658.2012.08521.x ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaoran Qin · 2 shared papers, 2012 · strength 0.06
- Paper Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. DOI 10.1111/j.1742-4658.2012.08521.x ↗
- Paper Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells. DOI 10.1016/j.gene.2012.04.088 ↗
Fu Li · 2 shared papers, 2012 · strength 0.06
- Paper Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. DOI 10.1111/j.1742-4658.2012.08521.x ↗
- Paper Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells. DOI 10.1016/j.gene.2012.04.088 ↗
Ming-hua Zhu · 1 shared paper, 2012 · strength 0.03
- Paper Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. DOI 10.1111/j.1742-4658.2012.08521.x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.